Lupus & antiphospholipid syndrome
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
Authors' conclusion
In a single-centre SLE cohort, cACEi/cARB use was not associated with absence of CD.
Study context
- Population
- Consecutive patients with SLE at a single academic health centre; ACR neuropsychological battery at baseline, 6 and 12 months, scores compared with sex- and age-matched controls
- Participants
- 300 patients676 visits
- Exposure
- Cumulative cACEi/cARB dose and odds of cognitive dysfunction
- Outcome
- CD defined as dysfunction in two or more cognitive domains
Methodological detailssingle-centre, generalised linear mixed modelling
- Single-centre
- Generalised linear mixed modelling
Main finding
As reported in the abstract
SLE-CD vs cumulative cACEi/cARB dose
- Cumulative cACEi/cARB dose was not protective against SLE-CD
Observational data: associations, not effects.
Further findings
Prevalence of cognitive dysfunction (CD)
- Met criteria for CD
- 116 (39%)
cACEi/cARB treatment
- Treated with a cACEi or cARB
- 53 (18%)
- Mean cumulative dose (equivalent ramipril dose)
- 236 mg/kg
Other factors associated with SLE-CD
- Caucasian ethnicity, current employment and AZA cumulative dose each associated with reduced odds of SLE-CD
- Increasing Fatigue Severity Scale score associated with increased odds of CD
Original publication
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE. Lupus Sci Med. Published 10 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →